March 21, 2025 07:00 AM EDT

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

ENDPOINTS

→ Brian Stephenson has stepped down after more than five years as CFO of BridgeBio, and president Tom Trimarchi will take over. Trimarchi was promoted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

ENDPOINTS

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking ‘the big next step’ after AlphaFold 3

AstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron

Johnson & Johnson earmarks $55B to boost US capacity

Updated: FDA approves Alnylam’s Amvuttra in ATTR-CM, kicking off competition with Pfizer, BridgeBio

Novo Nordisk says new early R&D structure will ‘future-proof’ its business

Akeso shares new data for bispecific in cervical cancer; Pulmatrix to divest assets

Bridge­Bio, Ed­i­tas fi­nance chiefs de­part; For­mer FDA No. 2 joins Re­cur­sion's board

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board